Expert Review of Neurotherapeutics最新文献_第2页

The utility of magnetoencephalography in epilepsy and its implications for treatment.

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-02-22 DOI: 10.1080/14737175.2025.2470333

Samuel Molot-Toker, James T Rutka, Eisha Christian

引用次数: 0

Treatment options for post-traumatic epilepsy: an update on clinical and translational aspects. 创伤后癫痫的治疗方案：临床和转化方面的最新进展。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-02-20 DOI: 10.1080/14737175.2025.2469041

Marco Mula

{"title":"Treatment options for post-traumatic epilepsy: an update on clinical and translational aspects.","authors":"Marco Mula","doi":"10.1080/14737175.2025.2469041","DOIUrl":"10.1080/14737175.2025.2469041","url":null,"abstract":"Introduction: Post-traumatic epilepsy (PTE) accounts for 10% to 20% of all symptomatic epilepsies and 5% of all forms of epilepsy, and drug resistance is reported in up to 45% of cases.Areas covered: This is a focused narrative review that discusses the available data on the current and new PTE treatments, giving particular attention to the last 10 years.Expert opinion: Despite the disappointing results of many antiseizure medications (ASMs) in preventing epileptogenicity, it is still unclear whether the early intervention could lead to different clinical phenotypes in terms, for example, of seizure severity, drug resistance and comorbidity patterns. The same applies to compounds targeting neuroinflammation, oxidative stress and neurotransmission modulation. The heterogeneity of etiologies leading to PTE has limited the investigation and implementation of specific interventions. New studies must focus on identifying common pathways and mechanisms shared by different etiological processes, identifying biomarkers, and validating animal models of epileptogenesis concerning PTE. Drug repurposing research will facilitate rapid translation into clinical research. Multitarget drug combinations will also receive increasing attention. In terms of non-pharmacological treatments, Vagus Nerve Stimulation seems to be a good option, while epilepsy surgery and Deep Brain Stimulation deserve further attention.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1-8"},"PeriodicalIF":3.4,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143448708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The risks versus the benefits of pharmacological intervention in social anxiety disorder in children.

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-02-12 DOI: 10.1080/14737175.2025.2461763

Stefan G Hofmann, Chantal Kasch, Bruno Pereira, Carolina Barbosa, Giovanbattista Andreoli

引用次数: 0

Frontotemporal dementia. How to deal with its diagnostic complexity?

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-02-07 DOI: 10.1080/14737175.2025.2461758

Annibale Antonioni, Emanuela Maria Raho, Enrico Granieri, Giacomo Koch

{"title":"Frontotemporal dementia. How to deal with its diagnostic complexity?","authors":"Annibale Antonioni, Emanuela Maria Raho, Enrico Granieri, Giacomo Koch","doi":"10.1080/14737175.2025.2461758","DOIUrl":"10.1080/14737175.2025.2461758","url":null,"abstract":"Introduction: Frontotemporal dementia (FTD) encompasses a group of heterogeneous neurodegenerative disorders. Aside from genetic cases, its diagnosis is challenging, particularly in the early stages when symptoms are ambiguous, and structural neuroimaging does not reveal characteristic patterns.Areas covered: The authors performed a comprehensive literature search through MEDLINE, Scopus, and Web of Science databases to gather evidence to aid the diagnostic process for suspected FTD patients, particularly in early phases, even in sporadic cases, ranging from established to promising tools. Blood-based biomarkers might help identify very early neuropathological stages and guide further evaluations. Subsequently, neurophysiological measures reflecting functional changes in cortical excitatory/inhibitory circuits, along with functional neuroimaging assessing brain network, connectivity, metabolism, and perfusion alterations, could detect specific changes associated to FTD even decades before symptom onset. As the neuropathological process advances, cognitive-behavioral profiles and atrophy patterns emerge, distinguishing specific FTD subtypes.Expert opinion: Emerging disease-modifying therapies require early patient enrollment. Therefore, a diagnostic paradigm shift is needed - from relying on typical cognitive and neuroimaging profiles of advanced cases to widely applicable biomarkers, primarily fluid biomarkers, and, subsequently, neurophysiological and functional neuroimaging biomarkers where appropriate. Additionally, exploring subjective complaints and behavioral changes detected by home-based technologies might be crucial for early diagnosis.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1-35"},"PeriodicalIF":3.4,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An overview of the value of mTOR inhibitors to the treatment of epilepsy: the evidence to date.

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-02-06 DOI: 10.1080/14737175.2025.2462280

Patrick B Moloney, Norman Delanty

{"title":"An overview of the value of mTOR inhibitors to the treatment of epilepsy: the evidence to date.","authors":"Patrick B Moloney, Norman Delanty","doi":"10.1080/14737175.2025.2462280","DOIUrl":"10.1080/14737175.2025.2462280","url":null,"abstract":"Introduction: Dysregulated mechanistic target of rapamycin (mTOR) activity is implicated in seizure development in epilepsies caused by variants in mTOR pathway genes. Sirolimus and everolimus, allosteric mTOR inhibitors, are widely used in transplant medicine and oncology. Everolimus is approved for treating seizures in tuberous sclerosis complex (TSC), the prototype mTORopathy. Emerging evidence suggests that mTOR inhibitors could also be effective in other mTORopathies, such as DEPDC5-related epilepsy and focal cortical dysplasia type 2 (FCD2).Areas covered: This narrative review summarizes key regulatory proteins in the mTOR cascade and outlines epilepsy syndromes linked to variants in genes encoding these proteins, particularly TSC, GATOR1-related epilepsies, and FCD2. It discusses the clinical pharmacology of mTOR inhibitors and the evidence supporting their efficacy as antiseizure medications (ASM) in mTORopathies. Lastly, potential benefits of next-generation mTOR inhibitors for CNS indications are evaluated.Expert opinion: The therapeutic benefits of mTOR inhibitors in TSC are well-established, but their value in other mTORopathies remains uncertain. Despite targeting the underlying disease biology, their efficacy in TSC is not significantly different from other ASM, likely due in part to pharmacokinetic constraints. Next-generation mTOR inhibitors that address these limitations may offer improved response rates, but they are in the preclinical development phase.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1-17"},"PeriodicalIF":3.4,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143188806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Switching between anti-CGRP monoclonal antibodies in migraine prophylaxis.

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-02-05 DOI: 10.1080/14737175.2025.2461766

Michail Vikelis, Dimitrios Rikos, Andreas A Argyriou, Emmanouil V Dermitzakis, Anna P Andreou, Antonio Russo

{"title":"Switching between anti-CGRP monoclonal antibodies in migraine prophylaxis.","authors":"Michail Vikelis, Dimitrios Rikos, Andreas A Argyriou, Emmanouil V Dermitzakis, Anna P Andreou, Antonio Russo","doi":"10.1080/14737175.2025.2461766","DOIUrl":"10.1080/14737175.2025.2461766","url":null,"abstract":"Introduction: When a first anti-CGRP monoclonal antibody (anti-CGRP mAb) fails, switching to a different anti-CGRP mAb is an option often considered, despite the fact that this approach is not yet systemically studied.Methods: We present the findings of a systematic review conducted according to the PRISMA recommendations on published studies - of any design - investigating the clinical outcomes after switching for any reason to different anti-CGRP mAbs.Results: The literature search retrieved 76 records, while 19 papers were eventually reviewed. Most studies were retrospective and/or had a small sample size. A significant proportion of participants experienced an improved treatment response after switching between different anti-CGRP mAbs. Specifically, according to prospective studies' results, the median MMDs were reduced by 12.8 days after 6 months of switching, while up to 48% of episodic and 36% of the chronic migraine patients achieved a >50% response rate.Conclusions: Switching between different anti-CGRP mAbs may be beneficial, at least for some patients, and should be considered when therapy with a first anti-CGRP mAb fails for any reason. Larger prospective studies, employing standardized protocols for switching or comparative effectiveness trials between mAbs, are anticipated to elucidate this issue further.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1-16"},"PeriodicalIF":3.4,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Zonisamide oral suspension as adjunctive therapy for treating partial seizures in adults and in pediatric patients aged 16 years and older with epilepsy.

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-02-04 DOI: 10.1080/14737175.2025.2462287

Francesco Brigo, Simona Lattanzi

{"title":"Zonisamide oral suspension as adjunctive therapy for treating partial seizures in adults and in pediatric patients aged 16 years and older with epilepsy.","authors":"Francesco Brigo, Simona Lattanzi","doi":"10.1080/14737175.2025.2462287","DOIUrl":"10.1080/14737175.2025.2462287","url":null,"abstract":"Introduction: Zonisamide (ZNS), is an antiseizure medication (ASM) approved by the US FDA and the European Medicines Agency (EMA) for focal-onset seizures. An oral suspension formulation has recently been introduced to improve administration for specific patient populations, particularly those with swallowing difficulties.Areas covered: This article explores the new ZNS oral suspension, evaluating its pharmacokinetic benefits, impact on patient care, and adherence. Bioavailability studies confirm that the oral suspension is bioequivalent to ZNS capsules, though no additional clinical trials in epilepsy patients have been conducted. This review presents and discusses the oral suspension's benefits, such as ease of administration for those with swallowing difficulties and flexible dosing, while also addressing potential drawbacks, including dosing accuracy and stability issues.Expert opinion: The ZNS oral suspension allows additional flexibility for epilepsy management, particularly for patients unable to swallow capsules. Its bioavailability and specific formulation may improve adherence and seizure control.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1-5"},"PeriodicalIF":3.4,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The latest developments in synthetic approaches to Duchenne muscular dystrophy.

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-02-04 DOI: 10.1080/14737175.2025.2462281

Lucy M Johnson, Tariq G Pulskamp, Daniel J Berlau

{"title":"The latest developments in synthetic approaches to Duchenne muscular dystrophy.","authors":"Lucy M Johnson, Tariq G Pulskamp, Daniel J Berlau","doi":"10.1080/14737175.2025.2462281","DOIUrl":"10.1080/14737175.2025.2462281","url":null,"abstract":"Introduction: Duchenne muscular dystrophy (DMD) is a rare X-linked genetic disorder caused by mutations in the dystrophin gene, leading to an almost complete absence of dystrophin, which is essential for muscle cell structure and function. This resulting muscle deterioration and fibrosis, eventually causes respiratory failure and cardiomyopathy. While there is currently no cure, existing therapies aim to prolong survival and alleviate symptoms.Areas covered: This paper reviews current and emerging therapies for DMD, focusing on their safety and efficacy. Although corticosteroids remain the standard treatment, newly approved drugs such as exon-skipping therapies, vamorolone, delandistrogene moxeparvovec, and givinostat provide new treatment options. Additionally, future therapies, including gene therapy, stem cell treatments, and anti-fibrotic agents, show promise for clinical application.Expert opinion: Advancements in DMD treatments have expanded patient options. While gene therapy offers potential for correcting the genetic defect and alleviating symptoms, corticosteroids remain the most cost-effective and well-researched treatment. This is partly due to the lack of compelling long-term safety and efficacy data for gene therapies. The accelerated FDA review process has enabled faster approval of new medications; however many have provided minimal clinical benefit to patients. Despite these challenges, continued drug development and innovative research offer hope to patients.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1-11"},"PeriodicalIF":3.4,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143079139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Using oral topiramate for primary generalized and focal-to-bilateral tonic-clonic seizures in patients 2 years of age and older: a review of the literature. 使用口服托吡酯治疗 2 岁及以上患者的原发性全身强直阵挛发作和局灶至双侧强直阵挛发作：文献综述。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-02-01 Epub Date: 2024-10-17 DOI: 10.1080/14737175.2024.2417417

Slobodan M Janković, Dobrivoje Stojadinović, Vera Dabanović

{"title":"Using oral topiramate for primary generalized and focal-to-bilateral tonic-clonic seizures in patients 2 years of age and older: a review of the literature.","authors":"Slobodan M Janković, Dobrivoje Stojadinović, Vera Dabanović","doi":"10.1080/14737175.2024.2417417","DOIUrl":"10.1080/14737175.2024.2417417","url":null,"abstract":"Introduction: Topiramate is a drug belonging to the second generation of antiseizure arsenal, used to treat focal onset seizures without generalization, focal-to-bilateral tonic-clonic seizures, and primary generalized tonic-clonic seizures.Areas covered: The narrative evaluation of topiramate's clinical research that has been published in this article focuses on the medication's effectiveness and safety when used to treat primary generalized and focal-to-bilateral tonic-clonic seizures. From their founding to the present, the databases MEDLINE, SCOPUS, EBSCO, and GOOGLE SCHOLAR were searched.Expert opinion: Topiramate treatment has the obvious benefit of being effective in treating tonic-clonic seizures; nevertheless, it may have a drawback in that up to 56% of patients discontinue therapy due to its rather poor tolerability, particularly at doses exceeding 600 mg daily. Patients are most bothered by psychiatric and cognitive side effects, and then by appetite and weight decrease. While the onset of anorexia cannot be prevented by changing the dosage regimen, psychiatric and cognitive side effects can be mitigated by slowly titrating the topiramate dose.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"133-141"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The impact of cognitive reserve relative to risk of Alzheimer's disease and rate of progression: an up-to-date review of the literature. 认知储备对阿尔茨海默病风险和进展速度的影响：最新文献综述。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-02-01 Epub Date: 2024-12-27 DOI: 10.1080/14737175.2024.2445015

Jordan Beveridge, Poorva Sheth, Shaan Thakkar, Bret Silverglate, George Grossberg

{"title":"The impact of cognitive reserve relative to risk of Alzheimer's disease and rate of progression: an up-to-date review of the literature.","authors":"Jordan Beveridge, Poorva Sheth, Shaan Thakkar, Bret Silverglate, George Grossberg","doi":"10.1080/14737175.2024.2445015","DOIUrl":"10.1080/14737175.2024.2445015","url":null,"abstract":"Introduction: Cognitive reserve (CR) is a crucial factor in explaining individual differences in the risk of Alzheimer's disease (AD) and cognitive decline. CR refers to the brain's ability to cope with pathology through compensatory mechanisms. This review examines the various methods used to measure, predict, and influence CR.Areas covered: Based on a search of PubMed, PubMed Central, EMBASE, Scopus, and the Cochrane Library (up to 1 June 2024), this review addresses key CR proxies, highlighting their strengths and limitations. The review also explores established and emerging interventions. We critically evaluate the statistical methods used to measure CR and assess its practical application.Expert opinion: CR plays a crucial role in delaying the onset and progression of AD. Lifestyle choices and experiences build CR and impact cognitive aging. However, practical challenges remain in applying CR in clinical settings, particularly in individuals with advanced cognitive decline. Education, while commonly used as a proxy for CR, may not fully capture its complexity. Alternatives like occupational complexity could offer more practical measures, but their application is still evolving. Addressing these limitations is key to advancing dementia prevention strategies.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"175-187"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142853594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0